Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | HTStec | Live Cell & Kinetic HCS Imaging Trends 2008

Live Cell & Kinetic HCS Imaging Trends 2008

HTStec's Live Cell & Kinetic HCS Imaging Trends 2008 report was published on 22 December 2008. This 54 page report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on live cell and kinetic high content screening (HCS) imaging carried out in December 2008. The objectives were to comprehensively document current use, interest and requirements for live cell and kinetic HCS imaging. It also attempts to identify emerging applications, market opportunities, unmet needs and demand for live cell and kinetic HCS imaging products. The report is based on 79 responses. Equal emphasis was given to soliciting opinion from pharmaceutical & biotech companies, academic laboratories and research organizations. The majority of labs contacted were in North America and Europe.

Executive Summary

o This market report summarizes the results of HTStec's global web-based benchmarking survey on live cell and kinetic high content screening (HCS) imaging carried out in December 2008.

o The study was initiated by HTStec to meet the specific needs, interests and focus of the survey sponsors. The main objectives of the study were to comprehensively document current use, interest and requirements for live cell and kinetic HCS imaging. It also attempts to identify emerging applications, market opportunities, unmet needs and demand for live cell and kinetic HCS imaging products.

o Equal emphasis was given to soliciting opinion from pharmaceutical & biotech companies; academic laboratories and research organizations. The majority of labs contacted were in North America and Europe.

o The survey looked at the following aspects of live cell and kinetic HCS imaging as practiced today (2008) and in some cases as predicted for the future (2010): level of current use of HCS imaging instruments; use of fixed cell HCS assays in primary screening and typical screening metrics; interest and use of live cell end point, live cell kinetic, and live cell fast response kinetic (after a liquid dispense) HCS imaging assays; % of HCS assays that image live cells; % of HCS assays that involve a liquid dispense followed by fast response kinetic (sequential) imaging; use of live cell HCS assays in primary screening and typical screening metrics; HCS instruments they have access to and use today; plans to purchase new live cell and kinetic HCS imaging instruments; preferred instrument configuration; high content assays respondent's most want to apply live cell and kinetic HCS imaging to, and the assays confocal requirement; interest in applications; areas where it is expected to make the greatest impact; advantages of greatest relevance; factors that limit ability to make maximum use of instrumentation; what is needed to grow the market; throughput requirements and assay expectations; time course requirements; environmental control requirements; liquid handling requirements; whether a medium throughput fast response kinetic imager could substitute for FLIPR-like devices; budget for consumables and its breakdown; instrument manufacturer most associated with desirable attributes, and the emphasis given to these attributes in purchasing decisions; and the need for improved instruments.

o The survey questionnaire consisted of 27 multi-choice questions. In addition, there were 5 questions related solely to survey demographics.

o The survey collected 79 responses (54 complete and 25 partially filled out) from 70 different organisations. Survey responses were geographically split: 56% North America, 38% Europe, 5% Asia (Excluding Japan) and 1% Rest of World.

o Survey respondents were drawn from persons or groups actively involved in HCS/HCA, with experience of or an interest in applying live cell and kinetic HCS imaging in the future.

o Respondents came from 35 University/Research Institute/Government Lab; 16 Medium-Small Pharma & All Biotech; 15 Large Pharma; 8 Other; and 5 Contract Research Organisations.

o Survey respondents represented: 21 Life Science Research labs; 13 labs with Multiple Drug Discovery Roles; 10 Assay Development labs; 9 Basic Research labs; 7 Other labs; 6 Primary Screening labs; 5 Hits-To-Leads labs; 3 Leads-To-Candidate labs; 2 Therapeutic Area labs; 2 Secondary Screening labs; and 1 Compound Profiling lab.

o Most survey respondents had a senior job role or position which was in descending order: 17 Research Scientists; 13 Senior Scientist/Research Associates; 12 Section/Group Leaders; 6 Lab/Research Manager/Coordinators; 6 Directors; 6 Other Job Roles; 5 Department Heads; 4 Principle Investigators; 4 Professor/Assistant Professors; 3 Post-docs; and 3 Vice Presidents.

o Survey results were expressed as an average of all survey respondents. In addition, the majority of the data was reanalyzed after sub-division into the following 5 survey groups: 1) Large Pharma; 2) Medium/Small Pharma & All Biotech; 3) University/Research Institute/Government Laboratory; 4) Europe; and 5) North America.

o The majority of respondents were making frequent (>50% of time) use of HCS imaging instruments.

o 44% of respondents were using fixed cell HCS assays in primary screening today.

o In terms of actual use of live cell imaging assays today (2008) 23% of respondents were investigating live cell end point HCS imaging assays, 18% live cell kinetic assays, and 1% fast response kinetic HCS imaging assays following a liquid dispense.

o A median of 10% of all HCS assays done today (2008) used live cells (i.e. do not image fixed cells).

o A median of 0% of all live cell HCS assays undertaken today (2008) involve a liquid dispense followed by fast response kinetic imaging.

o The use of live cell imaging in primary screening has so far been rather limited.

o The Thermo Scientific Cellomics ArrayScan® HCS Reader was the HCS instrument that most respondents have access to or use today. It was followed by the Thermo Scientific Cellomics ArrayScan VTI HCS Reader, then the GE Healthcare IN Cell Analyzer 1000 and the PerkinElmer Opera.

o 40% of respondents have an interest in purchasing a new live cell and kinetic HCS imager over the coming years. Greatest interest was expressed for purchasing the PerkinElmer Opera and Thermo Scientific Cellomics ArrayScan VTI HCS Reader. Details of 38 purchasing intentions are given in the report.

o Based on the current (2008) use of installed HCS imagers fitted with a live cell imaging option Thermo Scientific has the greatest market share.

o Based on interest to purchase new live cell & kinetic HCS imagers over the coming few years (up to 2010) it was estimated that PerkinElmer will achieve greatest market share.

o The HCS instrument configuration of greatest interest to respondents was an HCS imager integrated into an automated HCS system that is fully configured for all aspects of HCS.

o The HCS assays respondents were most interested in applying live cell and kinetic HCS imaging to were toxicity (cell health and proliferation) and receptors (internalization and recycling). Most respondent's confocal requirement for these assays was 'nice to have'.

o Live cell analysis on individual cells providing cell-specific results, drug toxicity and MOA studies were the application areas where respondents most want to use live cell and kinetic imaging.

o Live cell and kinetic HCS imaging is expected to impact across multiple drug discovery areas in the coming years.

o The ability to automate live cell incubation and image capture was ranked the most relevant advantage of live cell and kinetic HCS imaging.

o The cost of instrumentation was rated the factor that most limited respondent's ability to make maximum use of their kinetic analysis of live cellular events.

o Improved ways of delivering probes into living cells and targeting specific proteins or organelles was rated the factor that needed most improvement to grow the market for live cell & kinetic imaging.

o The median time course requirements today (2008) when undertaking kinetic analysis of live cellular events were: 1) without a liquid dispense a data read interval every 1 minute, with a total experiment duration of 24 hours; 2) after a liquid dispense a data read interval of once every 1 sec, with a total experiment duration of 10 min.

o The environmental control requirements most wanted for all types of live cell and kinetic imaging assays were: Temperature - ambient to 37oC; CO2 - 5% CO2; Humidity - >95% Humidity.

o The first choice live cell and kinetic HCS imaging manufacturer most associated with the following attributes were: Thermo Scientific for instrument reliability/robustness, automated processing and user-friendly setup & assay design software, and application expertise & support; PerkinElmer for technically innovative and good after-sales field support & service; Thermo Scientific and Molecular Devices (MDS) jointly most associated with image analysis capability/features; and No Manufacturer was most associated with value for money. Instrument reliability/robustness was rated the most important manufacturer attribute when purchasing/selecting a new live cell and kinetic HCS imager.

o The median live cell and kinetic HCS imaging consumables budget was $10K-$25K/lab/year in 2008. The greatest proportion this budget was allocated to commercial bulk reagents.

o Several bottom-up models were developed to estimate the markets for specific live cell and kinetic HCS imaging consumables and instruments using respondent data derived from this survey.

o The markets for live cell and kinetic HCS imaging consumables today was estimated to be around $11million and for imagers that are exclusively purchased for their live cell and kinetic functionality to be around 80 units (estimated value in excess of $40 million) spread over the next 3 years.

o The full report provides the data, details of the breakdown of the responses for each question and the estimates for the future (2010). It also highlights several differences between the survey groups.

Format - PDF Published - 2008
Table of Contents
Price: $2,475.00 / €1,655.78

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions